Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

Related Keywords

United States , ,Biomedical Advanced Research ,Linkedin ,Exchange Commission ,Us Congress ,Nasdaq ,Prnewswire Soligenix Inc ,European Medicines Agency ,Twitter ,Defense Threat Reduction Agency ,Development Authority ,Soligenix Inc ,Our Public Health Solutions ,National Institute Of Allergy ,Randomized Study ,Continuous Treatment Expected ,Extend Results ,Statistically Significant Phase ,About Hybryte ,About Cutaneoust Cell Lymphoma ,Public Health Solutions ,National Institute ,Infectious Diseases ,Project Bioshield ,Priority Review Voucher ,Soligenix ,Nc ,